E-mail  |   Log in
News Center
Ningbo Aucheer Biotechnology Co., Ltd
audir
audir
School of Diagnostics | A study on the pregnancy outcome of 532 patients with preeclampsia

School of Diagnostics | A study on the pregnancy outcome of 532 patients with preeclampsia

(Summary description)

School of Diagnostics | A study on the pregnancy outcome of 532 patients with preeclampsia

(Summary description)

 

Preeclampsia (PE) is a pregnancy-specific disease characterized by abnormally elevated blood pressure after 20 weeks of gestation, accompanied by maternal multiple organ dysfunction and abnormal fetal intrauterine conditions.It seriously affects the health of mothers and babies and is one of the main reasons for the increase in mortality of pregnant women and perinatal infants.

 

In recent years, the research on the pathogenesis of PE has made great progress. At present, it is generally believed that PE is a systemic systemic disease characterized by extensive vascular endothelial damage. Its early-onset and late-onset PE (appears after 34 weeks of gestation) have Different pathophysiological processes. Although more attention has been paid to PE at home and abroad, it is mostly based on basic research, and systemic clinical case studies and analysis are few. This study focuses on the complications and pregnancy outcomes of 532 PE patients in order to increase the further research on PE. Awareness, to provide valuable reference data for preventing and controlling the occurrence of PE.

 

 

The clinical data of 26,206 pregnant women who were expected to give birth and gave birth at the Daping Hospital of the Army Military Medical University from January 1, 2013 to April 30, 2019 were collected. First, several types of comorbidities that affected the analysis of pregnancy outcomes were excluded, a total of 2997 cases, multiple births 629 cases of pregnancy. The 23209 included cases were divided into observation group (n=532) and control group (n=22677) according to whether the final diagnosis was PE. Among them, the observation group was divided into mild PE group (n=134) and severe PE group ( n=398).

 

  Comparison of the two groups of pregnant women's age, parity, delivery method and gestational week  

 

Compared with the control group, the observation groupThe proportion of pregnant and lying-in women is relatively high,They were 29.2% in the mild PE group and 20.6% in the severe PE group; the cesarean section rate was extremely high, 70.1% in the mild PE group and 94.2% in the severe PE group; and the therapeutic preterm delivery rate was extremely high 55.0% in the severe PE group. See Table 1 for specific data.

 

 

  Preeclampsia group has higher pregnancy complications or complications than the control group

 

The incidence of hypothyroidism during pregnancy and intrahepatic cholestasis of pregnancy (ICP) in the mild PE group (26.9% and 10.5% respectively), the incidence of hypothyroidism during pregnancy and the incidence of ICP in the severe PE group (respectively 23.9%, 9.3%) were significantly higher than those of the control group (17.5%, 3.5%, respectively, P<0.05 or P<0.01); the incidence of placental abruption in the severe PE group (3.8%) was significantly higher than that of the control group (0.6%) , P<0.01); the incidence of gestational diabetes (GDM) in the mild PE group (41.8%) was significantly higher than that of the control group (30.0%, P<0.01); the incidence of umbilical cord around the neck (17.6%) in the severe PE group was significantly lower than The control group (25.1%, P<0.01); the incidence of premature rupture of membranes (12.7% in the mild PE group and 8.8% in the severe PE group) was significantly lower than the control group (27.0%, P<0.01).There was no significant difference in the incidence of scarred uterus and hyperthyroidism between the mild and severe PE groups and the control group (P>0.05, Table 2).

 

 

Newborn weight rate in preeclampsia group

The incidence of infants younger than gestational age is higher than that of the control group

 

Compared with the control group, the observation group has a higher incidence of low birth weight and less than gestational age infants. Among them, the mild PE group was 23.1% and 7.5%, and the severe PE group was 43.3% and 22.1%; severe PE The incidence of stillbirth in the group (7.3%) was significantly higher than that of the control group (0.7%, P<0.01). See Table 3 for specific data.

 

 

The pregnancy outcome of PE patients was significantly worse than that of normal pregnant women during the same period.As the pathogenesis of PE is not yet fully understood, in order to improve the health of pregnant women and newborns, and reduce the incidence of complications, prenatal examinations and health care during pregnancy in relatively backward areas should be increased, which is conducive to early detection and Intervene in hypertension during pregnancy to prevent serious adverse pregnancy outcomes.At the same time, obstetricians should pay more attention to PE to achieve early diagnosis and early treatment. In addition, prenatal education about PE should be strengthened for patients with PE who have been diagnosed.

 

  Healthy women and children Aucheer in action  

 

Ningbo Aocheng focuses on providing reliable, fast and convenient in vitro diagnostic reagents for clinics from early detection, diagnosis, prevention and detection of diseases, and is committed to providing professional clinical diagnosis solutions for women and children’s health.By Aucheer PlGF test reagent will usher in a new era of preeclampsia risk assessment and management.

Original Source

Zhu Dawei, Liu Yang. A study on the pregnancy outcome of 532 patients with preeclampsia. People's Liberation Army Medical Journal.

相关资讯

Aucheer
Contact:86-574-87732259
Technical Support:400-008-6588
Aucheer
Business Mailbox:info1@aucheer.net
HR Mailbox :hr@aucheer.net
Aucheer
Address: No. 885, Chunhua Road, Haishu District, Ningbo City, Zhejiang Province
North 4th Floor, Science and Technology Building, Ningbo Haichuang Park
Aucheer
Auchen Bio
Aucheer
Auchen Medical

© 2021 Ningbo Aucheer Biotechnology Co., Ltd | 浙ICP备17032133号-2Powered by www.300.cn